Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
BioRestorative Therapies, Inc. - Common Stock
(NQ:
BRTX
)
1.550
-0.040 (-2.52%)
Streaming Delayed Price
Updated: 1:00 PM EDT, Jul 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about BioRestorative Therapies, Inc. - Common Stock
< Previous
1
2
Next >
BioRestorative Announces Share Repurchase Program
June 17, 2025
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
Via
PressReach
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
June 13, 2025
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based
Via
PressReach
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team
June 10, 2025
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based
Via
PressReach
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
June 09, 2025
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based
Via
PressReach
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
April 23, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
April 23, 2025
Via
TheNewswire.com
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
April 16, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
April 16, 2025
By Meg Flippin Benzinga
Via
TheNewswire.com
BioRestorative Therapies (NASDAQ:BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
May 15, 2024
Via
ACCESSWIRE
BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society (ORS) 2024 Annual Meeting
February 14, 2024
Via
ACCESSWIRE
Roth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”
September 18, 2023
Via
ACCESSWIRE
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
August 30, 2023
Via
ACCESSWIRE
BioRestorative Therapies Gains Additional Investor Confidence As Insider Dale Broadrick, CEO Lance Alstodt Purchase Thousands of Shares
August 02, 2023
Via
ACCESSWIRE
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion
July 31, 2023
Via
ACCESSWIRE
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State
July 21, 2023
Via
ACCESSWIRE
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
July 07, 2023
Via
ACCESSWIRE
BioResorative CEO is Featured in An Interview With SmallCaps Daily
June 26, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It
June 15, 2023
Via
ACCESSWIRE
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ:BRTX) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
May 12, 2023
Via
ACCESSWIRE
BioRestorative Therapies, Inc. (NASDAQ: BRTX) Featured in Coverage of the Inaugural EF Hutton Global Conference
May 02, 2023
Via
Investor Brand Network
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
March 31, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Topics
Intellectual Property
BRTX’s ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
March 09, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Receives Notice of Third US Patent Related to ThermoStem IP
March 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
February 10, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Topics
Intellectual Property
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) Eyes Continued Growth of Patent Family for ThermoStem(R) Program
February 08, 2023
Via
Investor Brand Network
Topics
Intellectual Property
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
February 03, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
January 26, 2023
By Faith Ashmore, Benzinga
Via
TheNewswire.com
Topics
Intellectual Property
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
December 06, 2022
From
BioRestorative Therapies, Inc
Via
GlobeNewswire
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
December 05, 2022
From
BioRestorative Therapies, Inc
Via
GlobeNewswire
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference
November 29, 2022
Via
Investor Brand Network
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.